SCLY

Summary

SCLY (selenocysteine lyase, HGNC:18161) is a protein-coding gene on chromosome 2q37.3, encoding Selenocysteine lyase (Q96I15). Catalyzes the decomposition of L-selenocysteine to L-alanine and elemental selenium.

Selenocysteine lyase (SCLY; EC 4.4.1.16) catalyzes the pyridoxal 5-prime phosphate-dependent conversion of L-selenocysteine to L-alanine and elemental selenium (Mihara et al., 2000 [PubMed 10692412]).

Source: NCBI Gene 51540 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 90 total
• Druggable target: yes
• MANE Select transcript: NM_016510

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:18161
Approved symbol	SCLY
Name	selenocysteine lyase
Location	2q37.3
Locus type	gene with protein product
Status	Approved
Aliases	SCL
Ensembl gene	ENSG00000132330
Ensembl biotype	protein_coding
OMIM	611056
Entrez	51540

Gene structure

Transcript identifiers

Ensembl transcripts: 26 — 15 protein_coding, 6 retained_intron, 3 nonsense_mediated_decay, 2 protein_coding_CDS_not_defined

ENST00000254663, ENST00000409736, ENST00000412508, ENST00000413463, ENST00000416757, ENST00000423324, ENST00000431487, ENST00000433750, ENST00000437134, ENST00000440143, ENST00000443532, ENST00000446202, ENST00000450965, ENST00000463433, ENST00000480357, ENST00000480859, ENST00000482031, ENST00000487197, ENST00000497256, ENST00000497951, ENST00000651534, ENST00000904188, ENST00000904189, ENST00000904190, ENST00000904191, ENST00000940678

RefSeq mRNA: 1 — MANE Select: NM_016510 NM_016510

CCDS: CCDS2524

Canonical transcript exons

ENST00000254663 — 12 exons

Exon	Start	End
ENSE00001623065	238061001	238061143
ENSE00001914431	238098202	238099413
ENSE00003493278	238083248	238083354
ENSE00003520822	238082045	238082209
ENSE00003521332	238093861	238093944
ENSE00003551615	238096801	238096876
ENSE00003580996	238064357	238064469
ENSE00003592015	238069297	238069477
ENSE00003625048	238091218	238091254
ENSE00003627610	238081709	238081836
ENSE00003628860	238068065	238068165
ENSE00003635770	238094420	238094522

Expression profiles

Bgee: expression breadth ubiquitous, 180 present calls, max score 92.25.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 8.6852 / max 54.6202, expressed in 1718 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
26319	8.1320	1705
26320	0.5531	315

Top tissues by expression

287 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right lobe of liver	UBERON:0001114	92.25	gold quality
body of pancreas	UBERON:0001150	88.82	gold quality
granulocyte	CL:0000094	85.99	gold quality
right hemisphere of cerebellum	UBERON:0014890	85.59	gold quality
cerebellar hemisphere	UBERON:0002245	85.20	gold quality
cerebellar cortex	UBERON:0002129	84.98	gold quality
left testis	UBERON:0004533	84.73	gold quality
right testis	UBERON:0004534	84.62	gold quality
pancreas	UBERON:0001264	84.10	gold quality
mucosa of transverse colon	UBERON:0004991	83.43	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	82.04	gold quality
testis	UBERON:0000473	81.83	gold quality
monocyte	CL:0000576	81.78	gold quality
cerebellum	UBERON:0002037	81.69	gold quality
ganglionic eminence	UBERON:0004023	81.38	gold quality
leukocyte	CL:0000738	81.27	gold quality
stromal cell of endometrium	CL:0002255	81.15	gold quality
islet of Langerhans	UBERON:0000006	81.11	gold quality
right lobe of thyroid gland	UBERON:0001119	81.11	gold quality
body of uterus	UBERON:0009853	81.11	gold quality
small intestine Peyer’s patch	UBERON:0003454	81.06	gold quality
mononuclear cell	CL:0000842	81.02	gold quality
apex of heart	UBERON:0002098	80.89	gold quality
metanephros cortex	UBERON:0010533	80.69	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	80.39	gold quality
ventricular zone	UBERON:0003053	80.36	gold quality
left uterine tube	UBERON:0001303	80.02	gold quality
lower esophagus	UBERON:0013473	80.02	gold quality
lower esophagus muscularis layer	UBERON:0035833	80.02	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	79.87	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-MTAB-7606	no	361.93
E-ANND-3	no	3.08

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

40 targeting SCLY, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-9-3P	99.96	70.88	2068
HSA-MIR-8063	99.91	69.76	3146
HSA-MIR-7845-5P	99.88	64.88	771
HSA-MIR-202-5P	99.78	67.65	991
HSA-MIR-4319	99.76	69.83	2586
HSA-MIR-4320	99.75	65.80	793
HSA-MIR-92A-2-5P	99.75	67.01	2164
HSA-MIR-4524A-3P	99.72	66.85	2406
HSA-MIR-3685	99.62	68.83	1621
HSA-MIR-497-3P	99.61	69.71	1990
HSA-MIR-1249-5P	99.61	66.55	2049
HSA-MIR-6797-5P	99.61	66.55	2084
HSA-MIR-141-5P	99.57	67.86	897
HSA-MIR-3128	99.50	67.85	1258
HSA-MIR-5697	99.39	67.74	1249
HSA-MIR-125A-5P	99.36	70.59	1640
HSA-MIR-125B-5P	99.36	70.36	1662
HSA-MIR-488-5P	99.28	68.12	821
HSA-MIR-3978	99.24	68.39	2201
HSA-MIR-670-3P	99.03	68.88	2404
HSA-MIR-181A-2-3P	98.91	67.60	1168
HSA-MIR-4424	98.91	70.33	1145
HSA-MIR-384	98.71	67.34	1229
HSA-MIR-518C-5P	98.53	69.20	1640
HSA-MIR-6509-3P	98.32	67.33	1343
HSA-MIR-6732-3P	98.17	67.52	802
HSA-MIR-299-3P	97.73	66.67	773
HSA-MIR-890	97.47	68.67	982
HSA-MIR-4475	97.36	66.95	761

Literature-anchored findings (GeneRIF, showing 4)

• PMID:10692412 concerns mostly mouse selenocysteine lyase, however, refers to the sequence of the N-terminal region of putative human protein. (PMID:10692412)
• Results confirm that HCV core protein is associated with specific changes in mRNA expression, including the gene for selenocysteine lyase, which may be involved in the pathophysiology of hepatocellular carcinoma. (PMID:16925092)
• A reaction mechanism whereby the Selenocysteine over Cysteine specificity is achieved using a combination of chemical and physico-mechanical control mechanisms. (PMID:22291978)
• the X-ray crystal structure of human selenocysteine lyase and the key residue that provides the selenocysteine specificity (PMID:22295093)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	scly	ENSDARG00000073813
mus_musculus	Scly	ENSMUSG00000026307
rattus_norvegicus	Scly	ENSRNOG00000020083
caenorhabditis_elegans		WBGENE00017442

Paralogs (1): NFS1 (ENSG00000244005)

Protein

Protein identifiers

Selenocysteine lyase — Q96I15 (reviewed: Q96I15)

All UniProt accessions (12): Q96I15, A0A0A0MQU4, C9JNL5, F8WBU3, F8WCL3, H7C1N7, H7C277, H7C280, H7C2H3, H7C2M1, H7C3V9, H7C4A1

UniProt curated annotations — full annotation on UniProt →

Function. Catalyzes the decomposition of L-selenocysteine to L-alanine and elemental selenium.

Subunit / interactions. Homodimer.

Subcellular location. Cytoplasm. Cytosol.

Induction. Up-regulated in acute glomerulonephritis. Regulated by JUN/AP-1.

Similarity. Belongs to the class-V pyridoxal-phosphate-dependent aminotransferase family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q96I15-1	1	yes
Q96I15-2	2

RefSeq proteins (1): NP_057594* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000192	Aminotrans_V_dom	Domain
IPR015421	PyrdxlP-dep_Trfase_major	Homologous_superfamily
IPR015422	PyrdxlP-dep_Trfase_small	Homologous_superfamily
IPR015424	PyrdxlP-dep_Trfase	Homologous_superfamily
IPR016454	Cysteine_dSase	Family

Pfam: PF00266

Enzyme classification (BRENDA):

• EC 4.4.1.16 — selenocysteine lyase (BRENDA: 19 organisms, 40 substrates, 34 inhibitors, 18 Km, 8 kcat entries)

Substrate kinetics (BRENDA)

3 substrates with measured Km, best-characterized 3. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
L-SELENOCYSTEINE	0.2–9.9	15
L-CYSTEINE SULFINATE	8.6–30	2
BETA-CHLORO-L-ALANINE	3.1	1

Catalyzed reactions (Rhea), 1 shown:

• L-selenocysteine + AH2 = hydrogenselenide + L-alanine + A + H(+) (RHEA:11632)

UniProt features (46 total): helix 16, strand 12, turn 6, modified residue 3, sequence variant 3, sequence conflict 2, chain 1, region of interest 1, active site 1, splice variant 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
3GZD	X-RAY DIFFRACTION	1.8
3GZC	X-RAY DIFFRACTION	2.1

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96I15-F1	91.14	0.85

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 388 (s-selanylcysteine intermediate)

Post-translational modifications (3): 1, 129, 259

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-2408508	Metabolism of ingested SeMet, Sec, MeSec into H2Se
R-HSA-1430728	Metabolism
R-HSA-2408522	Selenoamino acid metabolism
R-HSA-71291	Metabolism of amino acids and derivatives

MSigDB gene sets: 130 (showing top): GOBP_ALPHA_AMINO_ACID_METABOLIC_PROCESS, BLALOCK_ALZHEIMERS_DISEASE_UP, GOBP_ORGANIC_ACID_CATABOLIC_PROCESS, GARCIA_TARGETS_OF_FLI1_AND_DAX1_DN, GOBP_ORGANIC_ACID_METABOLIC_PROCESS, GOBP_SMALL_MOLECULE_CATABOLIC_PROCESS, SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_UP, GOBP_AMINO_ACID_CATABOLIC_PROCESS, DANG_BOUND_BY_MYC, HAMAI_APOPTOSIS_VIA_TRAIL_DN, SENESE_HDAC3_TARGETS_DN, NUYTTEN_EZH2_TARGETS_DN, BENPORATH_MYC_MAX_TARGETS, GOMF_AMINO_ACID_BINDING, GOMF_PROTEIN_DIMERIZATION_ACTIVITY

GO Biological Process (2): amino acid metabolic process (GO:0006520), L-selenocysteine catabolic process (GO:0016261)

GO Molecular Function (7): selenocysteine lyase activity (GO:0009000), amino acid binding (GO:0016597), transferase activity (GO:0016740), protein homodimerization activity (GO:0042803), vitamin B6 binding (GO:0070279), protein binding (GO:0005515), lyase activity (GO:0016829)

GO Cellular Component (4): Golgi apparatus (GO:0005794), cytosol (GO:0005829), catalytic complex (GO:1902494), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Selenoamino acid metabolism	1
Metabolism of amino acids and derivatives	1
Metabolism	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	2
catalytic activity	2
cytoplasm	2
cellular anatomical structure	2
primary metabolic process	1
modified amino acid catabolic process	1
L-amino acid catabolic process	1
proteinogenic amino acid catabolic process	1
carbon-sulfur lyase activity	1
identical protein binding	1
protein dimerization activity	1
vitamin binding	1
heterocyclic compound binding	1
endomembrane system	1
intracellular membrane-bounded organelle	1
protein-containing complex	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

1633 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SCLY	SEPHS2	Q99611	752
SCLY	SEPSECS	Q9HD40	716
SCLY	PSTK	Q8IV42	711
SCLY	SELENOK	Q9Y6D0	658
SCLY	SELENOM	Q8WWX9	645
SCLY	EEFSEC	P57772	644
SCLY	SECISBP2	Q96T21	643
SCLY	SELENOS	Q9BQE4	643
SCLY	SEPHS1	P49903	634
SCLY	SELENOF	O60613	633
SCLY	SELENOP	P49908	626
SCLY	CTH	P32929	589
SCLY	SELENON	Q9NZV5	560
SCLY	SELENOT	P62341	519
SCLY	SELENOV	P59797	506
SCLY	TRNAU1AP	Q9NX07	506

IntAct

20 interactions, top by confidence:

A	B	Type	Score
CDK2	CCNE2	psi-mi:“MI:0914”(association)	0.940
SCLY	LNX2	psi-mi:“MI:0915”(physical association)	0.670
LNX2	SCLY	psi-mi:“MI:0915”(physical association)	0.670
EIF1AD	NAXD	psi-mi:“MI:0914”(association)	0.620
APBA3	CLSTN1	psi-mi:“MI:0914”(association)	0.530
TERF2IP	SCLY	psi-mi:“MI:0915”(physical association)	0.510
CREB3	SCLY	psi-mi:“MI:0915”(physical association)	0.370
Ncaph	ATP5MF-PTCD1	psi-mi:“MI:0914”(association)	0.350
TFG	NCOA4	psi-mi:“MI:0914”(association)	0.350
Atp7a	RTL8C	psi-mi:“MI:0914”(association)	0.350
VPS18	DNAJB5	psi-mi:“MI:0914”(association)	0.350
Mcm3	ELL2	psi-mi:“MI:0914”(association)	0.350
EXOSC5	PAPD5	psi-mi:“MI:0914”(association)	0.350
RANBP1	RGPD3	psi-mi:“MI:0914”(association)	0.350
ATG16L1	ESYT2	psi-mi:“MI:0914”(association)	0.350
MTPN	PLCG1	psi-mi:“MI:0914”(association)	0.350
SCLY	TERF2IP	psi-mi:“MI:0915”(physical association)	0.000
SCLY		psi-mi:“MI:0915”(physical association)	0.000

BioGRID (48): CCBL1 (Co-fractionation), HYI (Co-fractionation), IDE (Co-fractionation), NUTF2 (Co-fractionation), SCLY (Co-fractionation), SCLY (Co-fractionation), SCLY (Co-fractionation), SCLY (Co-fractionation), SCLY (Co-fractionation), SCLY (Co-fractionation), SCLY (Co-fractionation), WDR1 (Co-fractionation), SCLY (Two-hybrid), SCLY (Two-hybrid), SCLY (Affinity Capture-MS)

ESM2 similar proteins: A2VDS1, A4SP14, A4VNY2, A4XY43, A5GFY8, A6V0U8, A7H804, A7MBC0, A8GHY3, B0VD51, B0VNW2, B0YLW6, B2HZI5, B4UCP2, B7H3H0, B7I5Q3, B7UWH7, B8JC53, C1DE68, O31269, O43175, O49543, O60028, O74351, O75600, O88986, P0DN31, P25374, Q02RW8, Q0P5L8, Q10G56, Q1H361, Q2INI7, Q5BJY6, Q5R7M2, Q5U4Q9, Q60HD7, Q61753, Q66IQ6, Q68FT9

Diamond homologs: A1KUK1, A2VDS1, A4WDB1, A5I4Z9, A6TCF1, A7FWJ9, A7H804, A7MU48, A7ZPX4, A8A336, A8EYH9, A8F204, A8GHY3, A8GNU0, A8GSG4, A8GWB2, A9M029, A9MHJ4, A9N1X5, B0BXX6, B0YLW6, B1IWD1, B1LNI6, B1XB05, B2US50, B4T0S2, B4TDB6, B4TRX5, B4UCP2, B5BAW6, B5F1C0, B5FR85, B5R5A2, B5RD12, B5XNJ7, B5Z104, B6I5A2, B6JKF2, B7LDC2, B7M7N3

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

90 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	78
Likely benign	6
Benign	4

Top pathogenic / likely-pathogenic (0)

SpliceAI

2724 predictions. Top by Δscore:

Variant	Effect	Δscore
2:238064352:TTCA:T	acceptor_loss	1.0000
2:238064353:TCA:T	acceptor_loss	1.0000
2:238064355:A:AG	acceptor_gain	1.0000
2:238064355:A:T	acceptor_loss	1.0000
2:238064355:AG:A	acceptor_gain	1.0000
2:238064356:G:GT	acceptor_gain	1.0000
2:238064356:GG:G	acceptor_gain	1.0000
2:238064356:GGA:G	acceptor_gain	1.0000
2:238064356:GGAA:G	acceptor_gain	1.0000
2:238064356:GGAAA:G	acceptor_gain	1.0000
2:238064465:AGCAG:A	donor_loss	1.0000
2:238064466:GCAG:G	donor_gain	1.0000
2:238064468:AGG:A	donor_loss	1.0000
2:238064468:AGGT:A	donor_loss	1.0000
2:238064469:GGTA:G	donor_loss	1.0000
2:238064471:T:A	donor_loss	1.0000
2:238068053:T:TA	acceptor_gain	1.0000
2:238073848:G:GG	donor_gain	1.0000
2:238081707:A:AG	acceptor_gain	1.0000
2:238081707:AGC:A	acceptor_gain	1.0000
2:238081708:G:GC	acceptor_gain	1.0000
2:238081708:GCG:G	acceptor_gain	1.0000
2:238082041:TCAGC:T	acceptor_loss	1.0000
2:238082042:CAGCC:C	acceptor_loss	1.0000
2:238082043:A:AG	acceptor_gain	1.0000
2:238082043:A:C	acceptor_loss	1.0000
2:238082044:G:A	acceptor_loss	1.0000
2:238082044:G:GA	acceptor_gain	1.0000
2:238082044:GC:G	acceptor_gain	1.0000
2:238082044:GCC:G	acceptor_gain	1.0000

AlphaMissense

2909 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:238098266:A:C	S417R	0.996
2:238098268:C:A	S417R	0.996
2:238098268:C:G	S417R	0.996
2:238064370:G:C	D35H	0.995
2:238064372:C:A	D35E	0.994
2:238064372:C:G	D35E	0.994
2:238069428:C:A	H145Q	0.993
2:238069428:C:G	H145Q	0.993
2:238082208:A:T	K259M	0.993
2:238083348:G:C	R293T	0.993
2:238091227:C:A	N298K	0.992
2:238091227:C:G	N298K	0.992
2:238098318:T:C	L434P	0.992
2:238064371:A:T	D35V	0.991
2:238064447:T:A	N60K	0.991
2:238064447:T:G	N60K	0.991
2:238083348:G:T	R293M	0.991
2:238083349:G:C	R293S	0.991
2:238083349:G:T	R293S	0.991
2:238094494:C:A	N360K	0.991
2:238094494:C:G	N360K	0.991
2:238082129:G:C	D233H	0.990
2:238082130:A:T	D233V	0.990
2:238082209:G:C	K259N	0.990
2:238082209:G:T	K259N	0.990
2:238069433:C:T	S147F	0.989
2:238093919:G:C	R327P	0.989
2:238064371:A:C	D35A	0.988
2:238069426:C:G	H145D	0.988
2:238081826:G:T	G201V	0.988

dbSNP variants (sampled 300 via entrez): RS1000009707 (2:238087096 A>G), RS1000142871 (2:238064269 C>T), RS1000267118 (2:238085737 A>G), RS1000296805 (2:238085534 C>T), RS1000297315 (2:238066479 G>A,T), RS1000371579 (2:238085444 T>G), RS1000405249 (2:238084125 G>C), RS1000485341 (2:238091716 A>G), RS1000550200 (2:238066231 C>A), RS1000598253 (2:238084080 C>T), RS1000616715 (2:238077891 G>C), RS1000650988 (2:238083739 G>A), RS1000688461 (2:238079601 T>G), RS1000796617 (2:238096757 C>G,T), RS1000859908 (2:238079931 A>G)

Disease associations

OMIM: gene MIM:611056 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6066434 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.05	Kd	890.7	nM	CHEMBL5653589
6.05	ED50	890.7	nM	CHEMBL5653589

PubChem BioAssay actives

1 with measured affinity, of 2 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149352: Binding affinity to human SCLY incubated for 45 mins by Kinobead based pull down assay	kd	0.8907	uM

CTD chemical–gene interactions

27 total (human), top 27 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, increases expression, increases methylation	3
sodium arsenite	decreases expression	2
Smoke	decreases expression, decreases reaction	2
Tetrachlorodibenzodioxin	decreases expression	2
Tretinoin	decreases expression	2
Cyclosporine	decreases expression, increases expression	2
afuresertib	decreases expression	1
sodium arsenate	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
cobaltous chloride	decreases expression	1
potassium chromate(VI)	decreases expression, affects cotreatment	1
4-aminophenylarsenoxide	affects binding, decreases reaction	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
K 7174	decreases expression	1
Decitabine	decreases expression, decreases reaction	1
Arsenic Trioxide	affects binding, decreases reaction	1
Acetaminophen	decreases expression	1
Cisplatin	decreases expression	1
Demecolcine	decreases expression	1
Dibutyl Phthalate	affects cotreatment, increases expression	1
Enzyme Inhibitors	increases O-linked glycosylation, decreases activity	1
Ethyl Methanesulfonate	decreases expression	1
Formaldehyde	decreases expression	1
Hydrogen Peroxide	affects expression	1
Tetradecanoylphorbol Acetate	affects cotreatment, increases expression	1
Vincristine	decreases expression	1
Antirheumatic Agents	decreases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5652394	Binding	Binding affinity to human SCLY incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.